RxDoctor Payments Data

Amy Golob

Adult Health · York, PANPI 1114358421

Payments from drug & device makers

$2,351in general payments, 2019–2025

Across 72 payments — averaging $32.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$698
  • Impulse Dynamics (USA) Inc.$340
  • Boston Scientific$245
  • AstraZeneca$239
  • Actelion Pharmaceuticals US, Inc.$154
  • Bridgebio Pharma, Inc.$121
  • plus $554 from 12 others

What the payments were for

  • Food & beverage$2,351100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,351 in reported general payments places this provider in the 80th percentile of 899 adult health providers in Pennsylvania.

See all adult health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$54,713
Medicare patients
235
Services billed
779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis17$429,068
EntrestoSacubitril/Valsartan475$404,697
EliquisApixaban310$259,796
JardianceEmpagliflozin291$237,299
FarxigaDapagliflozin Propanediol92$76,275
XareltoRivaroxaban23$16,597
Metoprolol Succinate501$6,813
Bumetanide177$6,611
Torsemide187$4,759
BrilintaTicagrelor11$4,655
Potassium Chloride264$4,001
Furosemide820$3,780
Spironolactone630$2,869
Carvedilol340$2,253
Atorvastatin Calcium195$2,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$18$688,864327 claims
AstraZenecaFarxiga, Brilinta$239$80,931103 claims
Johnson & JohnsonXarelto$15$16,59723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 899 adult health providers in Pennsylvania.

Other adult health in York

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →